RESUMEN
BACKGROUND: Chagas disease (ChD) is the most important endemy in Latin America. Some patients, develop chronic Chagasic cardiopathy (CCC) years after the acute phase. It is unknown if patients infected by the oral route have higher risk of developing early CCC. METHODS AND FINDINGS: A prospective cohort study was conducted to assess morbidity and mortality during 10 years observation in 106 people simultaneously infected and treated in the largest known orally transmitted ChD outbreak in 2007. A preschooler died during the acute phase, but thereafter was no mortality associated to ChD. All acute phase findings improved in the first-year post-treatment. Each person was evaluated 8.7 times clinically, 6.4 by electrocardiogram (ECG)/Holter, and 1.7 by echocardiogram. Based on prevalence, the number of people who had any abnormalities (excluding repolarization abnormalities and atrial tachycardia which decreased) was higher than 2007, since they were found at least once between 2008-2017. However, when we evaluated incidence, except for clinical bradycardia and dizziness, it was observed that the number of new cases of all clinical and ECG findings decreased at the end of the follow-up. Between 2008-2017 there was not incidence of low voltage complex, 2nd degree AV block, long QT interval, left bundle branch block or left ventricular dysfunction that allowed the diagnosis of CCC. Total improvement prevailed over the persistence of all clinical and ECG/Holter findings, except for sinus bradycardia. Incomplete right bundle branch block, sinus bradycardia and/or T-wave inversion were diagnosed persistently in 9 children. The second treatment did not have significant influence on the incidence of clinical or ECG/Holter findings. CONCLUSIONS: At the end of the 10-year follow-up, there were not clinical or ECG/Holter criteria for classifying patients with CCC. The incidence of arrhythmias and repolarization abnormalities decreased. However, special attention should be paid on findings that not revert as sinus bradycardia, or those diagnosed persistently in all ECG as sinus bradycardia, incomplete right bundle branch block or T-wave inversion. Early diagnosis and treatment may have contributed to the rapid improvement of these patients. In ChD follow-up studies prevalence overestimates the real dimension of abnormalities, the incidence looks as a better indicator.
Asunto(s)
Bradicardia , Enfermedad de Chagas , Niño , Humanos , Bradicardia/epidemiología , Bloqueo de Rama/epidemiología , Estudios de Seguimiento , Estudios Prospectivos , Arritmias Cardíacas , Enfermedad de Chagas/complicaciones , Enfermedad de Chagas/epidemiología , Electrocardiografía , Brotes de EnfermedadesRESUMEN
The oral transmission of Chagas disease (oCD) in Venezuela announced its appearance in 2007. Different from other populations affected by oCD and despite close supervision during treatment with nitroheterocyclic drugs, the result was treatment failure. We studied genetic features of natural bloodstream parasite populations and populations after treatment of nine patients of this outbreak. In total, we studied six hemoculture isolates, eight Pre-Tx blood samples, and 17 samples collected at two or three Post-Tx time-points between 2007 and 2015. Parasitic loads were determined by quantitative polymerase chain reaction (qPCR), and discrete typing units (DTU), minicircle signatures, and Tcntr-1 gene sequences were searched from blood samples and hemocultures. Half-maximal inhibitory concentration (IC50) values were measured from the hemocultures. All patients were infected by TcI. Significant decrease in parasitic loads was observed between Pre-Tx and Post-Tx samples, suggesting the evolution from acute to chronic phase of Chagas disease. 60% of intra-DTU-I variability was observed between Pre-Tx and Post-Tx minicircle signatures in the general population, and 43 single-nucleotide polymorphisms (SNPs) were detected in a total of 12 Tcntr-1 gene sequences, indicative of a polyclonal source of infection. SNPs in three post-Tx samples produced stop codons giving rise to putative truncated proteins or displaced open reading frames, which would render resistance genes. IC50 values varied from 5.301 ± 1.973 to 104.731 ± 4.556 µM, demonstrating a wide range of susceptibility. The poor drug response in the Pre-Tx parasite populations may be associated with the presence of naturally resistant parasite clones. Therefore, any information that can be obtained on drug susceptibility from in vitro assays, in vivo assays, or molecular characterization of natural populations of Trypanosoma cruzi becomes essential when therapeutic guidelines are designed in a given geographical area.
Asunto(s)
Enfermedad de Chagas , Trypanosoma cruzi , Humanos , Trypanosoma cruzi/genética , Venezuela/epidemiología , Genotipo , Enfermedad de Chagas/tratamiento farmacológico , Enfermedad de Chagas/epidemiología , Enfermedad de Chagas/parasitología , Brotes de Enfermedades , Inmunidad InnataRESUMEN
La enfermedad de Chagas (ECh) es una parasitosis del grupo de enfermedades desatendidas de la OMS. Endémica del continente americano, la transmisión se realiza en ciclos selvático, peridomiciliario y domiciliario. Epidemiológicamente, los caninos y felinos constituyen una fuente importante de infección y son centinelas de la transmisión. El perro es un hospedador común e importante del parásito ya que la presencia y número de caninos infectados en la vivienda del hombre constituyen factores de riesgo de transmisión doméstica de Trypanosoma cruzi. El presente estudio reporta la seroprevalencia de la infección por T. cruzi en la bioregión centro norte de Venezuela (Distrito Capital, Chichiriviche de la Costa del Estado La Guaira y parte del Estado Miranda), en 301 perros y 49 gatos empleando el ensayo inmunoenzimatico (ELISA). La prevalencia global en perros fue del 30,2 % en las tres zonas estudiadas mientras que en gatos fue de 40,8 %. Con relación al sexo de los animales, se encontró una prevalencia general de perros hembras del 27,6 % y para los perros machos del 33,1%. Los gatos machos presentaron una prevalencia mayor que las hembras en todas las localidades. Tanto en perros como en gatos la distribución de seropositividad fue mayor en animales intradomicilio. Se evidenció diferencia en los valores de ELISA-IgG para las poblaciones de perros muestreados en la localidad de Petare comparado con perros presentes en la localidad de Aricagua (perros de caza), (p=0,006). En líneas generales, esta última localidad presentó una media de densidad óptica para la prueba de ELISA-IgG de 0,959 [0,369 - 1,975]. La presencia de perros y gatos infectados es un factor de riesgo actual de infección por T. cruzi para el hombre tanto en el medio rural como en el urbano(AU)
Chagas disease (ChD) is a parasitic infection in the WHO Neglected Diseases group. Endemic to the american continent, transmission takes place in sylvatic, peridomiciliary and domestic cycles. Epidemiologically, canines and felines constitute an important source of infection and are sentinels of transmission. The dog is a common and important host of the parasite, since the presence and number of infected canines in the man's house are risk factors for domestic transmission of Trypanosoma cruzi. This study reports the seroprevalence of T. cruzi infection in the north-central bioregion of Venezuela (Capital District, Chichiriviche de la Costa, La Guaira State, and part of Miranda State), in 301 dogs and 49 cats using the immunoenzymatic assay (ELISA). The overall prevalence in dogs was 30.2 % in the three studied areas, while in cats it was 40.8 %. Regarding the sex of the animals, a general prevalence of 27.6 % for female dogs and 33.1% for male dogs was found. Male cats presented a higher prevalence than females in all localities. In both, dogs and cats, the distribution of seropositivity was greater in indoor animals. There was of a difference in ELISA-IgG values for the populations of dogs sampled in the town of Petare compared to dogs present in the town of Aricagua (hunting dogs), (p=0.006). In general, this last locality presented a mean optical density for the ELISA-IgG test of 0.959 [0.369 - 1.975]. The presence of infected dogs and cats is a current risk factor for T. cruzi infection for man in both of them in the rural and in the urban environment(AU)
Asunto(s)
Animales , Trypanosoma cruzi , Gatos , Estudios Seroepidemiológicos , Perros , Enfermedades Parasitarias , Epidemiología , Enfermedades Transmisibles , Enfermedad de Chagas , Área UrbanaRESUMEN
Trypanosoma cruzi uses various mechanisms of infection to access humans. Since 1967, food contaminated with metacyclic trypomastigotes has triggered several outbreaks of acute infection of Chagas disease by oral transmission. Follow-up studies to assess the effectiveness of anti-parasitic treatment of oral outbreaks are rather scarce. Here, we report a 10-year laboratory follow-up using parasitological, serological, and molecular tests of 106 individuals infected in 2007 of the largest known outbreak of orally transmitted Chagas disease, which occurred in Caracas city, Venezuela. Before treatment (2007), specific IgA, IgM and IgG, were found in 71% (75/106), 90% (95/106) and 100% (106/106), respectively, in addition to 21% (9/43) parasitemia, Complement Mediated Lysis (CML) in 98% (104/106) and 79% (34/43) parasitic DNA for PCR. Blood culture detected parasitemia up to 18 months post-treatment in 6% (6/106) of the patients. In 2017, the original number of cases in the follow-up decreased by 46% and due to the country's economic situation, not all the trials could be carried out in the entire population. During follow-up, IgA and IgM disappeared promptly, with IgM persisting in 19% (20/104) of the patients three years after treatment. The anti-T. cruzi IgG remained positive 10 years later in 41% (20/49) of the individuals evaluated. CML remained positive seven years later in 79% (65/82) of the cases. PCR positive cases decreased after treatment but progressively recovered, being positive in 69% (32/46) of the individuals evaluated in 2017. The group of children (under 18 years of age) showed the highest PCR positivity with 76% (26/34) of the cases, but their parasitic load tended to diminish, while in adults the parasitic load regained their initial values. The simultaneous evaluation of serological tests and PCR of the patients allowed us to separate patients among responders and non-responders to the anti-parasitic treatment, and this information prompted us to apply a second anti-parasitic treatment in the group of non-responders. In this population not subjected to the like lihood of re-infection, adult patients were more likely to be non-responders when compared to children. These results suggest that rigorous laboratory follow-up with T. cruzi infectious biomarkers is essential to detect cases of parasite persistence.
Asunto(s)
Enfermedad de Chagas , Adulto , Anticuerpos Antiprotozoarios/análisis , Biomarcadores , Enfermedad de Chagas/diagnóstico , Enfermedad de Chagas/tratamiento farmacológico , Enfermedad de Chagas/epidemiología , Niño , Brotes de Enfermedades , Estudios de Seguimiento , Humanos , Estudios Seroepidemiológicos , Insuficiencia del Tratamiento , Venezuela/epidemiologíaRESUMEN
We aimed to characterize the genetic constitution of natural T. cruzi populations involved in an Oral Chagas Disease (OCD) outbreak at a rural school of the community of Chichiriviche de la Costa, Venezuela, which affected patients did not respond to the etiological treatment. Peripheral blood samples and/or hemocultures were obtained from twenty-nine OCD patients at time of diagnosis or along nine years of Post-treatment (Tx) follow-up. The IgG serology, T. cruzi discrete typing units (DTU), satellite DNA-qPCR parasitic loads, and minicircle signatures were determined at Pre-Tx and after Tx. The serological titles and parasitic loads changed after treatment, with a significant decrease of IgG titers (Spearman's r value= -0.961) and median parasite loads from 2.869 [IQR = 2.113 to 3.720] to 0.105 [IQR = -1.147 to 1.761] log10 par eq. /mL at Pre-Tx and Post-Tx, respectively, suggesting infection evolution from acute to chronic phase, without seroconversion or parasitological eradication, which was indicative of treatment failure. All patients were infected with T. cruzi DTU I populations. At Pre-Tx their median Jaccard genetic distances were 0.775 [IQR = 0.708 to 0.882], decreasing in genetic variability towards the end of follow-up (Mann-Whitney U test p= 0.0031). Interestingly, no Post-Tx minicircle signature was identical to its Pre-Tx counterpart population in a same patient, revealing selection of parasite subpopulations between the primary infection and Post-Tx. The parasitic populations isolated from hemocultures showed a lower number of bands in the minicircle signatures with respect to the signatures obtained directly from the patients' blood samples, demonstrating a process of parasitic selection and reduction of the population variability that initially infected the patients. Decrease of parasitic loads after treatment as well as Pre- and Post-Tx intra-TcI diversity might be a consequence of both, natural evolution of the acute infection to the chronic phase and persistence of refractory populations due to Tx selection.
Asunto(s)
Enfermedad de Chagas , Trypanosoma cruzi , ADN Protozoario , Estudios de Seguimiento , Humanos , Carga de Parásitos , Reacción en Cadena en Tiempo Real de la Polimerasa , Trypanosoma cruzi/genéticaRESUMEN
Accurate diagnostic tools and surrogate markers of parasitologic response to treatment are needed for managing Chagas disease. Quantitative real-time PCR (qPCR) is used for treatment monitoring, but variability in copy dosage and sequences of molecular target genes among different Trypanosoma cruzi strains limit the precision of quantitative measures. To improve qPCR quantification accuracy, we designed and evaluated a synthetic DNA molecule containing a satellite DNA (satDNA) repeat unit as standard for quantification of T. cruzi loads in clinical samples, independently of the parasite strain. Probit regression analysis established for Dm28c (TcI) and CL-Brener (TcVI) stocks similar 95% limit of detection values [0.903 (0.745 to 1.497) and 0.667 (CI, 0.113 to 3.927) copy numbers/µL, respectively] when synthetic DNA was the standard for quantification, allowing direct comparison of loads in samples infected with different discrete typing units. This standard curve was evaluated in 205 samples (38 acute oral and 19 chronic Chagas disease patients) from different geographical areas infected with various genotypes, including samples obtained during treatment follow-up; high agreement with parasitic load trends using standard curves based on DNA extracted from spiked blood with counted parasites was obtained. This qPCR-based quantification strategy will be a valuable tool in phase 3 clinical trials, to follow up patients under treatment or at risk of reactivation, and in experimental models using different parasite strains.
Asunto(s)
Enfermedad de Chagas/diagnóstico , ADN Protozoario/genética , ADN Satélite/genética , Variación Genética , Tipificación Molecular/métodos , Trypanosoma cruzi/genética , Secuencia de Bases , Enfermedad de Chagas/genética , Enfermedad de Chagas/parasitología , ADN Protozoario/análisis , ADN Satélite/análisis , Genotipo , Humanos , Reacción en Cadena en Tiempo Real de la PolimerasaRESUMEN
A Trypanosoma cruzi Loopamp kit was recently developed as a ready-to-use diagnostic method requiring minimal laboratory facilities. We evaluated its diagnostic accuracy for detection of acute Chagas disease (CD) in different epidemiological and clinical scenarios. In this retrospective study, a convenience series of clinical samples (venous blood treated with EDTA or different stabilizer agents, heel-prick blood in filter paper or cerebrospinal fluid samples (CSF)) from 30 infants born to seropositive mothers (13 with congenital CD and 17 noninfected), four recipients of organs from CD donors, six orally-infected cases after consumption of contaminated guava juice and six CD patients coinfected with HIV at risk of CD reactivation (N = 46 patients, 46 blood samples and 1 CSF sample) were tested by T. cruzi Loopamp kit (Tc LAMP) and standardized quantitative real-time PCR (qPCR). T. cruzi Loopamp accuracy was estimated using the case definition in the different groups as a reference. Cohen's kappa coefficient (κ) was applied to measure the agreement between Tc LAMP (index test) and qPCR (reference test). Sensitivity and specificity of T. cruzi Loopamp kit in blood samples from the pooled clinical groups was 93% (95% CI: 77-99) and 100% (95% CI: 80-100) respectively. The agreement between Tc LAMP and qPCR was almost perfect (κ = 0.92, 95% CI: 0.62-1.00). The T. cruzi Loopamp kit was sensitive and specific for detection of T. cruzi infection. It was carried out from DNA extracted from peripheral blood samples (via frozen EDTA blood, guanidine hydrochloride-EDTA blood, DNAgard blood and dried blood spots), as well as in CSF specimens infected with TcI or TcII/V/VI parasite populations. The T. cruzi Loopamp kit appears potentially useful for rapid detection of T. cruzi infection in congenital, acute and CD reactivation due to HIV infection.
Asunto(s)
Enfermedad de Chagas/sangre , Enfermedad de Chagas/diagnóstico , Técnicas de Amplificación de Ácido Nucleico/métodos , Trypanosoma cruzi/aislamiento & purificación , Enfermedad de Chagas/líquido cefalorraquídeo , Enfermedad de Chagas/congénito , Coinfección , ADN Protozoario/análisis , Femenino , Infecciones por VIH , Humanos , Lactante , Recién Nacido , Masculino , Reacción en Cadena en Tiempo Real de la Polimerasa/métodos , Estudios Retrospectivos , Sensibilidad y Especificidad , Receptores de Trasplantes , Trypanosoma cruzi/fisiologíaRESUMEN
La infección por Trypanosoma cruzi está garantizada por la presencia del parásito en muchos géneros animales incluido el hombre. Este a su vez, no solo adquiere el parásitoa través del vector (cutánea, por mucosas, oral) o por secreciones de didelfidos o accidentalmente por manipulación de material biológico infectante,sino también por la trasmisión hombre-hombre la cual aumenta la diseminación de la Enfermedad de Chagas aunque en menor proporción (trasmisión congénita, transfusional o por trasplante de tejidos). El parásito alcanza al feto in utero principalmente por su capacidad de atravesar la placenta especialmente después de la semana 20 cuando la barrera placentaria se adelgaza progresivamente. Sin embargo solo del 1 al 10% de los niños nacidos de madres con Enfermedad de Chagas desarrollan infección aguda variando de acuerdo al país, edad gestacional, al genotipo y carga del parásito entre varios factores. La clínica del neonato con T. cruzi va desde casos asintomáticos, bajo peso, prematuridad, hepatoesplenomegalia, dificultad respiratoria,hastael desenlace fatal. La prevención se basa en la detección por serología y tratamiento oportuno en niñas y mujeres antes del embarazo ya que los antiparasitarios específicos producen efectos adversos y en principio están contraindicados durante el embarazo. En cambio el tratamiento está indicado en el niño en cualquier momento cuando se demuestre la patología. El despistaje de la infección por T. cruzi debería ser obligatorio en toda Latinoamérica y en toda mujer latinoamericana en el mundo a fin de estar preparado para la atención postparto al infante y a la madre(AU)
Infection with Trypanosoma cruzi is guaranteed by the presence of the parasite in many animal genera including man. This in turn, not only acquires the parasite by contact with a vector (skin, mucoses and oral transmission) or by secretions of didelfides or accidentally by manipulation of infecting biological material, but also by man-man transmission which increases the spread of Chagas disease (congenital, transfusion or tissue transplant transmission). The parasite reaches the fetus in utero mainly due to its ability to cross the placenta especially after week 20 when the placental barrier becomes progressively thinner. However, only 1 to 10% of children born from mothers with Chagas disease develop acute infection, varying according to country, gestational age, genotype, and parasite load among various factors. The clinic of the neonate with T. cruzi ranges from asymptomatic cases, low weight, prematurity, hepatosplenomegaly, respiratory distress to the fatal outcome. Prevention is based on the detection by serology and timely treatment in girls and women before pregnancy since specific antiparasitic drugs produce adverse effects and are in principle contraindicated during pregnancy. Instead, treatment is indicated in the child at any time when the pathology is demonstrated. The screening of T. cruzi infection should be mandatory in all Latin America and in all Latin American women in the world in order to be prepared for the postpartum care of the infant and the mother(AU)
Asunto(s)
Humanos , Femenino , Embarazo , Enfermedad de Chagas/prevención & control , Enfermedad de Chagas/epidemiología , Transmisión Vertical de Enfermedad Infecciosa/prevención & control , Atención Posnatal , Venezuela/epidemiología , Estudios Seroepidemiológicos , Antiparasitarios/uso terapéuticoRESUMEN
La Toxoplasmosis y la Enfermedad de Chagas (ECh) son infecciones parasitarias frecuentes en Latinoamérica, capaces de ser transmitidas verticalmente durante el embarazo. Este trabajo tiene como objetivo determinar la seroprevalencia ante Trypanosoma cruzi (T. cruzi) y Toxoplasma gondii (T. gondii), en las embarazadas de la consulta prenatal del Ambulatorio Docente del Hospital Universitario de Caracas. Estudio analítico, prospectivo de corte transversal, realizado en 300 pacientes, en el lapso comprendido entre enero 2018 marzo 2019. El 31,66 % de la población estudiada presentó seropositividad para anticuerpos IgG específicos para T. gondii, avidez de IgG mayor al 50 % e IgM negativa en todas, resultados compatibles con la fase crónica de la infección. Al correlacionar con los factores de riesgo habituales para la transmisión de T. gondii destacaron el contacto con heces de gato (46,3 %) y el consumo de agua directamente del grifo (32,6 %). En el caso de la ECh se demostró la presencia de factores de riesgo en la población estudiada, como contacto con triatominos (51,45 %) y viviendas cercanas a vegetación (49 %), sin embargo, solo una embarazada (0,33 %) demostró seropositividad para T. cruzi sin presentar relación con los factores de riesgo estudiados. Se evidenció una seroprevalencia muy frecuente para T. gondii y menor para T. cruzi, con factores de riesgo para la trasmisión vectorial cutánea y oral muy altos, constituyéndo una amenaza tanto para la embarazada como para al feto. Se recomienda educar a la población para reducir su exposición a factores de riesgo.
Toxoplasmosis and Chagas Disease (ChD) are frequent parasitic infections in Latin America, capables of vertical transmission during pregnancy. The purpose of this article is to determine the seroprevalence against Trypanosoma cruzi (T. cruzi) and Toxoplasma gondii (T. gondii), in pregnant women attending the prenatal clinic of the "Hospital Universitario de Caracas". Analytical, prospective study of a transversal cohort, carried out in 300 patients, during the period January 2018 - March 2019. The 31.66 % of the analyzed population showed seropositivity for IgG specific antibodies for T. gondii, all displaying an avidity IgG greater than 50 % and negative IgM, corresponding to a chronic stage of the infection. When correlating with the usual risk factors for the transmission of T. gondii, it was highlighted the presence of contact with cat feces (46.3 %) and the consumption of water directly from the tap (32.6 %). While with Chagas Disease (ChD), the presence of risk factors for acquiring the infection were highly demonstrated in the population, such as contact with triatomines (51.45 %) and living close to vegetation (49 %), however, only one pregnant woman (0.33 %) presented seropositivity for T. cruzi, without being related to the known risk factors. We conclude that T. gondii presents a high seroprevalence and T. cruzi an infrequent seroprevalence in the covered population, with high risk factors for cutaneous and oral vector transmission, representing a threat for the mother and the fetus. We recommend educating the population to reduce their exposure to risk factors.
RESUMEN
BACKGROUND & OBJECTIVES: In Venezuela, Chagas disease (ChD) is considered a serious health problem, with about 6 million people at risk; and acute outbreaks due to oral transmission of Chagas Disease (OChD) are becoming increasingly important. In 2007 there was a major outbreak of OChD and although patients from this episode were treated with nifurtimox (Lampit®-Bayer), about 70% therapeutic failure was registered. These results led us to examine whether parasite's drug susceptibility was related to this therapeutic failure. METHODS: The Trypanosoma cruzi parasites were isolated by haemoculture of the peripheral blood drawn from the pre- and post-nifurtimox treated patients infected in the 2007 OChD outbreak at Caracas, Venezuela. The in vitro assays for drug testing were performed by the MTT methodology followed by calculation of inhibitory concentration-50 (IC50) values. RESULTS: Parasite isolates obtained from the infected patients prior and after nifurtimox treatment when subjected to variable concentrations of the drug showed great heterogeneity in susceptibility with IC50 values ranging from 4.07 ± 1.82 to 94.92 ± 7.24 µM. INTERPRETATION & CONCLUSION: The high heterogeneity in nifurtimox IC50 values in the isolates and clones from the OChD patients, suggests that the therapeutic failure to nifurtimox could be due in part to a phenotypic variability that existed in the wild parasite population at the original source of contamination. Though, further pharmacological studies are needed to confirm the existence of natural nifurtimox resistance in the parasite.
Asunto(s)
Enfermedad de Chagas/tratamiento farmacológico , Enfermedad de Chagas/parasitología , Nifurtimox/farmacología , Tripanocidas/farmacología , Trypanosoma cruzi/efectos de los fármacos , Enfermedad de Chagas/epidemiología , Brotes de Enfermedades , Resistencia a Medicamentos , Genotipo , Humanos , Concentración 50 Inhibidora , Insuficiencia del Tratamiento , Trypanosoma cruzi/genética , Venezuela/epidemiologíaRESUMEN
We describe the eleventh major outbreak of foodborne Trypanosoma cruzi transmission in urban Venezuela, including evidence for vertical transmission from the index case to her fetus. After confirming fetal death at 24 weeks of gestation, pregnancy interruption was performed. On direct examination of the amniotic fluid, trypomastigotes were detected. T. cruzi specific-polymerase chain reaction (PCR) also proved positive when examining autopsied fetal organs. Finally, microscopic fetal heart examination revealed amastigote nests. Acute orally transmitted Chagas disease can be life threatening or even fatal for pregnant women and unborn fetuses owing to vertical transmission. There is therefore an urgent need to improve national epidemiologic control measures.
Asunto(s)
Enfermedad de Chagas/transmisión , Muerte Fetal/etiología , Parasitología de Alimentos , Enfermedades Transmitidas por los Alimentos/parasitología , Transmisión Vertical de Enfermedad Infecciosa , Adolescente , Adulto , Enfermedad de Chagas/complicaciones , Enfermedad de Chagas/epidemiología , Brotes de Enfermedades , Femenino , Humanos , Hidropesía Fetal/parasitología , Reacción en Cadena de la Polimerasa , Embarazo , Población Urbana , Venezuela/epidemiología , Adulto JovenRESUMEN
We describe the eleventh major outbreak of foodborne Trypanosoma cruzi transmission in urban Venezuela, including evidence for vertical transmission from the index case to her fetus. After confirming fetal death at 24 weeks of gestation, pregnancy interruption was performed. On direct examination of the amniotic fluid, trypomastigotes were detected. T. cruzi specific-polymerase chain reaction (PCR) also proved positive when examining autopsied fetal organs. Finally, microscopic fetal heart examination revealed amastigote nests. Acute orally transmitted Chagas disease can be life threatening or even fatal for pregnant women and unborn fetuses owing to vertical transmission. There is therefore an urgent need to improve national epidemiologic control measures.
Asunto(s)
Humanos , Femenino , Embarazo , Adolescente , Adulto , Adulto Joven , Parasitología de Alimentos , Enfermedad de Chagas/transmisión , Transmisión Vertical de Enfermedad Infecciosa , Muerte Fetal/etiología , Enfermedades Transmitidas por los Alimentos/parasitología , Población Urbana , Venezuela/epidemiología , Hidropesía Fetal/parasitología , Reacción en Cadena de la Polimerasa , Brotes de Enfermedades , Enfermedad de Chagas/complicaciones , Enfermedad de Chagas/epidemiologíaRESUMEN
BACKGROUND: Two old drugs are the only choice against Trypanosoma cruzi and little is known about their secondary effects in the acute stage of oral-transmitted Chagas disease (ChD). METHODS: A cross-sectional analytical surveillance study was conducted in a sizable cohort of patients seen during the largest acute foodborne ChD microepidemic registered so far. Individuals were treated with benznidazole (BNZ) or nifurtimox (NFX). 'Common Terminology Criteria for Adverse Events' was assessed to categorize side effects according to severity. RESULTS: Out of 176 treatments applied, 79% had one or more adverse effects, which predominated in adults (97.8%) as compared to children (75.5%). Risk of side effects with NFX was significantly higher than BNZ. Four adults and a child treated with NFX had severe side effects (pulmonary infarction, facial paralysis, neutropenia, blurred vision, bone marrow hypoplasia) warranting hospitalization, and drug suspension. Adverse effects frequently reported with NFX were abdominal pain, hyporexia, weight loss, headache, nausea and lymphocytosis, whereas skin rash, neurosensory effects, hyporexia, fatigue, pyrosis, abdominal pain and eosinophilia were observed with BNZ. CONCLUSIONS: Frequency and severity of side effects during treatment of acute oral infection by T. cruzi demand direct supervision and close follow-up, even in those asymptomatic, to prevent life-threatening situations.
Asunto(s)
Enfermedad de Chagas/tratamiento farmacológico , Nifurtimox/efectos adversos , Nitroimidazoles/efectos adversos , Farmacovigilancia , Tripanocidas/efectos adversos , Enfermedad de Chagas/epidemiología , Estudios Transversales , Femenino , Humanos , Masculino , Nifurtimox/uso terapéutico , Nitroimidazoles/uso terapéutico , Tripanocidas/uso terapéutico , Trypanosoma cruzi/efectos de los fármacosRESUMEN
Oral transmission of Trypanosoma cruzi is a frequent cause of acute Chagas disease (ChD). In the present cross-sectional study, we report the epidemiological, clinical, serological and molecular outcomes of the second largest outbreak of oral ChD described in the literature. It occurred in March 2009 in Chichiriviche de la Costa, a rural seashore community at the central littoral in Venezuela. The vehicle was an artisanal guava juice prepared at the local school and Panstrongylus geniculatus was the vector involved. TcI genotype was isolated from patients and vector; some showed a mixture of haplotypes. Using molecular markers, parasitic loads were high. Eighty-nine cases were diagnosed, the majority (87.5%) in school children 6-15 years of age. Frequency of symptomatic patients was high (89.9%) with long-standing fever in 87.5%; 82.3% had pericardial effusion detected by echocardiogram and 41% had EKG abnormalities. Three children, a pregnant woman and her stillborn child died (5.6% mortality). The community was addressed by simultaneous determination of specific IgG and IgM, confirmed with indirect hemagglutination and lytic antibodies. Determination of IgG and IgA in saliva had low sensitivity. No individual parasitological or serological technique diagnosed 100% of cases. Culture and PCR detected T. cruzi in 95.5% of examined individuals. Based on the increasing incidence of oral acute cases of ChD, it appears that food is becoming one of the most important modes of transmission in the Amazon, Caribbean and Andes regions of America.
RESUMEN
Orally transmitted Chagas disease has become a matter of concern due to outbreaks reported in four Latin American countries. Although several mechanisms for orally transmitted Chagas disease transmission have been proposed, food and beverages contaminated with whole infected triatomines or their faeces, which contain metacyclic trypomastigotes of Trypanosoma cruzi, seems to be the primary vehicle. In 2007, the first recognised outbreak of orally transmitted Chagas disease occurred in Venezuela and largest recorded outbreak at that time. Since then, 10 outbreaks (four in Caracas) with 249 cases (73.5% children) and 4% mortality have occurred. The absence of contact with the vector and of traditional cutaneous and Romana's signs, together with a florid spectrum of clinical manifestations during the acute phase, confuse the diagnosis of orally transmitted Chagas disease with other infectious diseases. The simultaneous detection of IgG and IgM by ELISA and the search for parasites in all individuals at risk have been valuable diagnostic tools for detecting acute cases. Follow-up studies regarding the microepidemics primarily affecting children has resulted in 70% infection persistence six years after anti-parasitic treatment. Panstrongylus geniculatus has been the incriminating vector in most cases. As a food-borne disease, this entity requires epidemiological, clinical, diagnostic and therapeutic approaches that differ from those approaches used for traditional direct or cutaneous vector transmission.
Asunto(s)
Enfermedad de Chagas/epidemiología , Enfermedad de Chagas/transmisión , Brotes de Enfermedades/estadística & datos numéricos , Enfermedad de Chagas/diagnóstico , Humanos , Venezuela/epidemiologíaRESUMEN
Orally transmitted Chagas disease has become a matter of concern due to outbreaks reported in four Latin American countries. Although several mechanisms for orally transmitted Chagas disease transmission have been proposed, food and beverages contaminated with whole infected triatomines or their faeces, which contain metacyclic trypomastigotes of Trypanosoma cruzi, seems to be the primary vehicle. In 2007, the first recognised outbreak of orally transmitted Chagas disease occurred in Venezuela and largest recorded outbreak at that time. Since then, 10 outbreaks (four in Caracas) with 249 cases (73.5% children) and 4% mortality have occurred. The absence of contact with the vector and of traditional cutaneous and Romana’s signs, together with a florid spectrum of clinical manifestations during the acute phase, confuse the diagnosis of orally transmitted Chagas disease with other infectious diseases. The simultaneous detection of IgG and IgM by ELISA and the search for parasites in all individuals at risk have been valuable diagnostic tools for detecting acute cases. Follow-up studies regarding the microepidemics primarily affecting children has resulted in 70% infection persistence six years after anti-parasitic treatment. Panstrongylus geniculatus has been the incriminating vector in most cases. As a food-borne disease, this entity requires epidemiological, clinical, diagnostic and therapeutic approaches that differ from those approaches used for traditional direct or cutaneous vector transmission.
Asunto(s)
Humanos , Enfermedad de Chagas/epidemiología , Enfermedad de Chagas/transmisión , Brotes de Enfermedades/estadística & datos numéricos , Enfermedad de Chagas/diagnóstico , Venezuela/epidemiologíaRESUMEN
La mayor microepidemia de Enfermedad de Chagas (ECh) de transmisión oral (103 afectados) se detectó en 2007 en una escuela en Caracas, Venezuela. Este trabajo describe los hallazgos clínicos yde laboratorio en 22 personas hospitalizadas. Se investigó la presencia de parásitos y de anticuerposespecíficos IgM e IgG (ELISA y Hemaglutinación Indirecta). Se encontraron parásitos en 22,7por cento(5/22) individuos y anticuerpos anti-Trypanosoma cruzi en 86,3por cento (19/22). Los diagnósticosdiferenciales de ingreso fueron dengue, infección urinaria, histoplasmosis, polimiositis, enfermedad autoinmune y mononucleosis. Se encontró fiebre diaria y prolongada en 18/22 (81,8por cento) y edema en 9 (40,9por cento) personas. En 13/19 casos confirmados hubo afectación cardíaca, 7 (31,8por cento) con derrame pericárdico y uno (4,5por cento) con fibrilación auricular que ameritó cardioversión. Otros hallazgos fueron astenia, mialgias, cefalea, dolor precordial y abdominal. Hubo alteraciones en los valoresde troponina (8/11), VSG (8/14), PCR (14/16), LDH (8/9) y leucocitos (8/21). Tres personas no presentaron anticuerpos para T. cruzi y un caso confirmado falleció. La sospecha clínica de ECh transmitida por vía oral es difícil pues no hay asociación con el vector ni puerta de entrada del parásito y los síntomas que eventualmente pueden orientar el caso, usualmente son inespecíficos. La enfermedad aguda puede progresar a enfermedad severa cuando el diagnóstico y tratamientooportunos se retrasan.
Asunto(s)
Humanos , Enfermedad de Chagas/epidemiología , Enfermedad de Chagas/transmisión , Promoción de la Salud , Trypanosoma cruzi , VenezuelaRESUMEN
Orally transmitted Chagas disease (ChD), which is a well-known entity in the Brazilian Amazon Region, was first documented in Venezuela in December 2007, when 103 people attending an urban public school in Caracas became infected by ingesting juice that was contaminated with Trypanosoma cruzi. The infection occurred 45-50 days prior to the initiation of the sampling performed in the current study. Parasitological methods were used to diagnose the first nine symptomatic patients; T. cruzi was found in all of them. However, because this outbreak was managed as a sudden emergency during Christmas time, we needed to rapidly evaluate 1,000 people at risk, so we decided to use conventional serology to detect specific IgM and IgG antibodies via ELISA as well as indirect haemagglutination, which produced positive test results for 9.1%, 11.9% and 9.9% of the individuals tested, respectively. In other more restricted patient groups, polymerase chain reaction (PCR) provided more sensitive results (80.4%) than blood cultures (16.2%) and animal inoculations (11.6%). Although the classical diagnosis of acute ChD is mainly based on parasitological findings, highly sensitive and specific serological techniques can provide rapid results during large and severe outbreaks, as described herein. The use of these serological techniques allows prompt treatment of all individuals suspected of being infected, resulting in reduced rates of morbidity and mortality.
Asunto(s)
Anticuerpos Antiprotozoarios/sangre , Enfermedad de Chagas/diagnóstico , Brotes de Enfermedades , Inmunoglobulina G/sangre , Inmunoglobulina M/sangre , Trypanosoma cruzi/inmunología , Adulto , Enfermedad de Chagas/epidemiología , Enfermedad de Chagas/transmisión , Niño , ADN Protozoario/análisis , Ensayo de Inmunoadsorción Enzimática , Femenino , Pruebas de Hemaglutinación , Humanos , Masculino , Persona de Mediana Edad , Reacción en Cadena de la Polimerasa , Venezuela/epidemiologíaRESUMEN
Orally transmitted Chagas disease (ChD), which is a well-known entity in the Brazilian Amazon Region, was first documented in Venezuela in December 2007, when 103 people attending an urban public school in Caracas became infected by ingesting juice that was contaminated with Trypanosoma cruzi. The infection occurred 45-50 days prior to the initiation of the sampling performed in the current study. Parasitological methods were used to diagnose the first nine symptomatic patients; T. cruzi was found in all of them. However, because this outbreak was managed as a sudden emergency during Christmas time, we needed to rapidly evaluate 1,000 people at risk, so we decided to use conventional serology to detect specific IgM and IgG antibodies via ELISA as well as indirect haemagglutination, which produced positive test results for 9.1%, 11.9% and 9.9% of the individuals tested, respectively. In other more restricted patient groups, polymerase chain reaction (PCR) provided more sensitive results (80.4%) than blood cultures (16.2%) and animal inoculations (11.6%). Although the classical diagnosis of acute ChD is mainly based on parasitological findings, highly sensitive and specific serological techniques can provide rapid results during large and severe outbreaks, as described herein. The use of these serological techniques allows prompt treatment of all individuals suspected of being infected, resulting in reduced rates of morbidity and mortality.
Asunto(s)
Adulto , Niño , Femenino , Humanos , Masculino , Persona de Mediana Edad , Anticuerpos Antiprotozoarios/sangre , Enfermedad de Chagas/diagnóstico , Brotes de Enfermedades , Inmunoglobulina G/sangre , Inmunoglobulina M/sangre , Trypanosoma cruzi/inmunología , Enfermedad de Chagas/epidemiología , Enfermedad de Chagas/transmisión , ADN Protozoario/análisis , Ensayo de Inmunoadsorción Enzimática , Pruebas de Hemaglutinación , Reacción en Cadena de la Polimerasa , Venezuela/epidemiologíaRESUMEN
Chagas disease is an endemic zoonosis native to the Americas and is caused by the kinetoplastid protozoan parasite Trypanosoma cruzi. The parasite is also highly genetically diverse, with six discrete typing units (DTUs) reported TcI - TcVI. These DTUs broadly correlate with several epidemiogical, ecological and pathological features of Chagas disease. In this manuscript we report the most comprehensive evaluation to date of the genetic diversity of T. cruzi in Venezuela. The dataset includes 778 samples collected and genotyped over the last twelve years from multiple hosts and vectors, including nine wild and domestic mammalian host species, and seven species of triatomine bug, as well as from human sources. Most isolates (732) can be assigned to the TcI clade (94.1%); 24 to the TcIV group (3.1%) and 22 to TcIII (2.8%). Importantly, among the 95 isolates genotyped from human disease cases, 79% belonged to TcI - a DTU common in the Americas, however, 21% belonged to TcIV- a little known genotype previously thought to be rare in humans. Furthermore, were able to assign multiple oral Chagas diseases cases to TcI in the area around the capital, Caracas. We discuss our findings in the context of T. cruzi DTU distributions elsewhere in the Americas, and evaluate the impact they have on the future of Chagas disease control in Venezuela.